Therapy-related myeloid neoplasms
نویسندگان
چکیده
منابع مشابه
Therapy-related myeloid neoplasms.
Session 5 of 2007 Workshop of the Society for Hematopathology/European Association for Haematopathology focused on therapy-related myeloid neoplasms. This report discusses the diversity and relevance of clinical, pathologic, and genetic features and provides an update on the pathogenesis of these disorders. We highlight common diagnostic issues such as the differentiation between therapy-relate...
متن کاملTherapy - related myeloid neoplasms
Professor Eliane Gluckman is Past Head of the Hematology Bone Marrow Transplantation Unit, Hospital Saint Louis, Paris and currently Professor Emeritus of University Paris VII, Director of Eurocord, and President of the European School of Haematology. Dr. Vanderson Rocha is Scientific Director of Eurocord, Chair of the Acute Leukemia Working Party of EBMT and medical assistant of the HSCT unit ...
متن کاملTherapy-Related Myeloid Neoplasms
Hodgkin lymphoma (HL) is a malignancy of the lymphatic system with an incidence of 2 3/100.000/year in developed countries. With modern multi optionally combined with radiotherapy (RT), 80% to 90% of HL patients achieve long remission and can be considered cured. However, current standard approaches bear a considerable risk for the development of treatment research in HL is reducing the inciden...
متن کاملGenetic Pathways Leading to Therapy-Related Myeloid Neoplasms
Therapy-related myeloid neoplasm (t-MN) is a distinctive clinical syndrome occurring after exposure to chemotherapy or radiotherapy. t-MN arises in most cases from a multipotential hematopoietic stem cell or, less commonly, in a lineage committed progenitor cell. The prognosis for patients with t-MN is poor, as current forms of therapy are largely ineffective. Cytogenetic analysis, molecular an...
متن کاملTherapy-Related Myeloid Neoplasms in Patients Treated for Hodgkin Lymphoma
Hodgkin lymphoma (HL) is a malignancy of the lymphatic system with an incidence of 2-3/100.000/year in developed countries. With modern multi-agent chemotherapy protocols optionally combined with radiotherapy (RT), 80% to 90% of HL patients achieve long-term remission and can be considered cured. However, current standard approaches bear a considerable risk for the development of treatment-rela...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Haematologica
سال: 2009
ISSN: 0390-6078,1592-8721
DOI: 10.3324/haematol.2008.005157